The Beatrice Hunter Cancer Research Institute logo
  • BHCRI Seminar Series

    Friday, April 7, 2017

    • Time: 03:00 pm - 04:00 pm
    • Location: 2L7, Tupper Building Link, Dalhousie and listed videoconference sites
    • Presenter: Dr. Roy Duncan and Dr. Sandra Turcotte

    The Beatrice Hunter Cancer Research Institute Seminar Series Session will be held on Friday, 7 April 2017 from 3:00-4:00pm ADT in room 2-L7, 2nd floor, Tupper Building Link, Dalhousie University and by videoconference to the following sites:  

    •   Dalhousie Halifax –2L3, Second Floor, Tupper Link
    •   Georges Dumont Hospital — CHUDGLD - Sous-sol de l’Auberge Rm 012
    •   MUN – Meeting Room 4 (H2988)
    •   UNB Fredericton – 010 MacLaggan room 
    •   Dalhousie Truro –Room 211, Cox Building
    •   CBU – B260-C
    •   UNB St. John – DMNB Saint John 266

    This session is mandatory for CRTP Trainees. If trainees are unable to attend, please notify


    Enhanced Oncolytic Virotherapy using Reovirus FAST Proteins and Immunomodulation

    Presented by:

    Roy Duncan, PhD
    Professor and Killam Chair in Virology
    Department of Microbiology & Immunology and cross-appointed to Biochemistry and Molecular Biology, and Pediatrics
    Dalhousie University

    Dr. Roy Duncan is a Dalhousie University Research Professor and Killam Chair in Virology, and a Professor in the Department of Microbiology and Immunology with cross appointments in Biochemistry and Molecular Biology, and Pediatrics. The overarching theme of his CIHR- and NSERC-funded research program is viral protein-membrane interactions, exploiting unique and advantageous features of the reovirus fusion-associated small transmembrane (FAST) proteins to pursue several broad aims. His research has led to a revolutionary new model of protein-mediated membrane fusion, deciphered pathways regulating the formation and dynamics of intracellular membrane compartments and membrane microdomains, and to the discovery and 
    characterization of novel actin regulators involved in cancer cell migration and muscle cell development. He founded Fusogenix Inc to commercialize FAST proteins for use in lipid-based nanoparticle drug delivery platforms, and most recently increase the efficacy of oncolytic irotherapies.

    Synthetic Lethality to Improve Therapeutic Strategies in Renal Cell Carcinoma

    Presented by:

    Sandra Turcotte, PhD
    Assistant Professor
    Department of Chemistry and Biochemistry, Université de Moncton
    Researcher in Residence, Atlantic Cancer Research Institute
    Research Chair, Canadian Cancer Society, New Brunswick

    Dr. Sandra Turcotte is Assistant Professor at the Université de Moncton and Researcher in Residence at the Atlantic Cancer Research Institute since 2011. 
    She completed her PhD in Biochemistry at the Université du Québec à Montréal and Post-doctoral Fellowships at Stanford University in California and at the CRCHUM in Montreal. Her research focus is on developing new targeted therapy for kidney cancer based on synthetic lethality. Dr. Turcotte holds a Research Chair from the Canadian Cancer Society-New Brunswick.

Site by: Spectacle Group